Cytodyn Inc (CYDY) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Cytodyn Inc $0.05, price $0.21, upside -75.1%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Cytodyn Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $0.1100 – $2.46 · fair‑value band $0.0510 – $0.0595 · the $0.2050 price screens above the $0.0510 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Cytodyn in your weekly email
Every Wednesday you see whether Cytodyn is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19.
Show more
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Stock analysis
Cytodyn Inc (CYDY) currently trades at $0.2050, while our model-based Fair Value estimate is $0.0510, implying the stock looks roughly 301.9% overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.1100 per share, and 0 of the 7 models we run sit above the $0.2050 price.
Bear case: the Earnings-Based group reads lowest at $0.0200, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0510 (bear) to $0.0595 (bull), the price of $0.2050 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Cytodyn Inc reported revenue of $0 in FY2025 versus −$4.4M in FY2021. Reported net income was $3.7M in FY2025.
Key figures
Market cap $370M · EPS (TTM) $−0.0400 · Return on assets (EBIT) −209% · Free cash flow −$8.8M · Net debt $15.3M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).
What moves the price
The share trades about 45% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −75%, CYDY screens richer than that median.
Fair Value models
Bear $0.0510Fair Value $0.0510Bull $0.0595
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.1/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 650 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score53 · Above median
Fair Value upside−75% · Bottom 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−67% · Bottom 25%
Operating margin (TTM)0% · Above median
Growth and dividend
Revenue growth0% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cytodyn Inc Fair Value". https://www.fairvalue-calculator.com/stock/CYDY
Frequently asked questions
Is Cytodyn Inc (CYDY) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0510 versus a price of $0.2050, about −75% upside (overvalued).
What is the fair value of CYDY?
Our model-based fair value for Cytodyn Inc is $0.0510 (as of Sep 23, 2026), built from audited fundamentals. The current price: $0.2050.
What is the quality score of CYDY?
Cytodyn Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cytodyn Inc (CYDY)?
Our model-based price target is the fair value of $0.0510 (as of Sep 23, 2026) from 7 valuation models. Cautious scenario $0.0510, optimistic scenario $0.0595. It is a calculation from audited fundamentals, not an analyst target.
What is the Cytodyn Inc stock forecast for 2026?
Our models put fair value at $0.0510, about −75% upside versus a price of $0.2050 (overvalued). Cautious scenario $0.0510, optimistic scenario $0.0595. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Cytodyn Inc (CYDY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cytodyn Inc it is $0.0510 per share (as of Sep 23, 2026), against a price of $0.2050. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Cytodyn Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, CYDY trades above its calculated fair value: price $0.2050, fair value $0.0510, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYDY?
No. The price is what the market pays today ($0.2050); the fair value is what the company's own numbers justify ($0.0510). For Cytodyn Inc the two are $0.1540 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cytodyn Inc worth?
The market values Cytodyn Inc at about $370M (market capitalisation, as of Sep 23, 2026). Per share that is $0.2050; our models calculate a fair value of $0.0510 per share.
What do the bullish and bearish scenarios say about CYDY?
Our models span a range for Cytodyn Inc: cautious scenario $0.0510, base $0.0510, optimistic $0.0595 per share (as of Sep 23, 2026, price $0.2050). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cytodyn Inc (CYDY)?
Balance-sheet figures for Cytodyn Inc (as of Sep 23, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is CYDY from its 52-week high?
Cytodyn Inc trades at $0.2050, about 45% below its 52-week high of $0.3700 and 10% above the low of $0.1863 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0510 is for.
Which stocks are comparable to Cytodyn Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cytodyn Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.2050, calculated fair value $0.0510 (−75%), Quality Score 53/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CYDY calculated?
We run Cytodyn Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0510, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Cytodyn Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cytodyn Inc (CYDY)?
The closing price on Sep 23, 2026 was $0.2050. Our model-based fair value is $0.0510, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cytodyn Inc right now?
The price sits above even our optimistic bull case ($0.0595). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Cytodyn Inc
How large is the market capitalisation of Cytodyn Inc (CYDY)?
The market capitalisation of Cytodyn Inc is $370M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Cytodyn Inc (CYDY)?
Earnings per share at Cytodyn Inc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of Cytodyn Inc (CYDY)?
On an EBIT basis the return on assets of Cytodyn Inc is −209% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Cytodyn Inc (CYDY) generate?
The free cash flow of Cytodyn Inc is −$8.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cytodyn Inc (CYDY) carry?
The net debt of Cytodyn Inc is $15.3M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cytodyn Inc in the live analysis
One click puts Cytodyn Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026